JP2021047056A - 非侵襲的なHbA1c値の推定方法 - Google Patents
非侵襲的なHbA1c値の推定方法 Download PDFInfo
- Publication number
- JP2021047056A JP2021047056A JP2019168784A JP2019168784A JP2021047056A JP 2021047056 A JP2021047056 A JP 2021047056A JP 2019168784 A JP2019168784 A JP 2019168784A JP 2019168784 A JP2019168784 A JP 2019168784A JP 2021047056 A JP2021047056 A JP 2021047056A
- Authority
- JP
- Japan
- Prior art keywords
- value
- urinary
- hba1c
- zinc
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 230000002485 urinary effect Effects 0.000 claims abstract description 70
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000011701 zinc Substances 0.000 claims abstract description 46
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 46
- 108010075254 C-Peptide Proteins 0.000 claims abstract description 33
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims abstract description 31
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims abstract description 22
- 108091005995 glycated hemoglobin Proteins 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 12
- 108010014663 Glycated Hemoglobin A Proteins 0.000 abstract 3
- 210000002700 urine Anatomy 0.000 description 26
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 13
- 206010012601 diabetes mellitus Diseases 0.000 description 12
- 229940109239 creatinine Drugs 0.000 description 6
- 238000011282 treatment Methods 0.000 description 5
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000007486 appendectomy Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
1.対象者の尿中亜鉛値を指標として、糖化ヘモグロビン(HbA1c)値を推定する方法。
2.対象者の年齢、尿中亜鉛値、尿中Cペプチド値のうちいずれか2つ以上を指標として、糖化ヘモグロビン(HbA1c)値を推定する方法。
3.対象者の年齢、尿中亜鉛値、尿中Cペプチド値を指標として、糖化ヘモグロビン(HbA1c)値を推定する方法。
尿中の亜鉛濃度[μg/dL]、Cペプチド濃度[μg/dL]およびクレアチニン(Cre)濃度[g/mL]を測定し、尿中亜鉛値[μg/g Cre]、尿中Cペプチド値[μg/g Cre]を算出した。なお、尿中成分濃度は、食事や水分摂取、発汗などの影響を受けやすく、尿の濃さによって成分濃度が大きく変動するため、尿中亜鉛値、尿中Cペプチド値は、同時に測定したクレアチニン値との比率を求めるクレアチニン補正を行った値である。
推定糖化ヘモグロビン(HbA1c)値[%]
=(α1)×尿中亜鉛値[μg/g Cre]
+(β1)×尿中Cペプチド値[μg/g Cre]
+(γ1)×年齢
+(δ1)
(α1)は、0.001〜0.002が好ましく、0.0013〜0.0018がより好ましい。(β1)は、0.001〜0.01が好ましく、0.003〜0.007がより好ましい。(γ1)は、0.003〜0.013が好ましく、0.005〜0.011がより好ましい。(δ1)は、1〜10が好ましく、2〜6がより好ましい。
推定糖化ヘモグロビン(HbA1c)値[%]
=(α2)×尿中亜鉛値[μg/g Cre]
+(γ2)×年齢
+(δ2)
(α2)は、0.001〜0.002が好ましく、0.0013〜0.018がより好ましい。(γ2)は、0.005〜0.015が好ましく、0.008〜0.013がより好ましい。(δ2)は、1〜10が好ましく、2〜6がより好ましい。
推定糖化ヘモグロビン(HbA1c)値[%]
=(β2)×尿中Cペプチド値[μg/g Cre]
+(γ3)×年齢
+(δ3)
(β2)は、0.001〜0.01が好ましく、0.003〜0.007がより好ましい。(γ3)は、0.003〜0.013が好ましく、0.005〜0.011がより好ましい。(δ3)は、1〜10が好ましく、2〜6がより好ましい。
推定糖化ヘモグロビン(HbA1c)値[%]
=(α3)×尿中亜鉛値[μg/g Cre]
+(β3)×尿中Cペプチド値[μg/g Cre]
+(δ4)
(α3)は、0.001〜0.002が好ましく、0.0013〜0.0018がより好ましい。(β3)は、0.001〜0.01が好ましく、0.003〜0.007がより好ましい。(δ4)は、1〜10が好ましく、2〜6がより好ましい。
推定糖化ヘモグロビン(HbA1c)値[%]
=(α4)×尿中亜鉛値[μg/g Cre]
+(δ5)
(α4)は、0.001〜0.002が好ましく、0.0012〜0.0018がより好ましい。(δ5)は、1〜10が好ましく、2〜6がより好ましい。
20歳以上70歳未満の日本人男女316名(男性156名、女性160名)を対象に、背景調査(性別、生年月日、食事摂取調査アンケート)、尿中の亜鉛、Cペプチド、クレアチニン(Cre)濃度の測定、血清中の亜鉛濃度及び血中のHbA1c値の測定を実施した。
以下のとおり、除外規準を設けた。
1)重篤な既往歴及び消化管の切除手術歴がある方(虫垂切除を除く)
2)妊娠している方及び授乳中の方
3)アルコール多飲及び過度の喫煙の方
4)その他、試験責任医師により本試験参加に不適切と判断された方
対象者に、来院日の早朝第1尿(起床後すぐの尿)を10mL容量の採尿容器に採取させた。
尿中亜鉛濃度はメタロアッセイ亜鉛測定LS(メタロジェニクス株式会社製)、尿中Cペプチド濃度はルミパルスプレストCペプチド(富士レビオ株式会社製)を用い、ルミパルスプレストII(富士レビオ株式会社製)にて自動分析した。尿中Cre濃度は「セロテック」CRE−S(株式会社セロテック製)を用い、クリナライザ(JCA−BM6070)(日本電子株式会社製)により自動分析した。分析結果より、尿中の亜鉛濃度[μg/dL]、Cペプチド濃度[μg/dL]およびCre濃度[mg/dL]を得、尿中亜鉛値[μg/g Cre]、尿中Cペプチド値[μg/g Cre]を算出した。
HbA1cはデタミナーL HbA1c(協和メデックス株式会社製)を用いて、クリナライザ(JCA−BM9130、日本電子株式会社製)にて自動分析し、分析結果としてHbA1c値(%)を得た。
回帰分析により、相関係数および推定式を得た。
得られた尿中亜鉛値[μg/g Cre]、尿中Cペプチド値[μg/g Cre]、年齢から、以下の推定式1−1を得た。
(推定式1−1)
推定糖化ヘモグロビン(HbA1c)値[%]
=0.0014702×尿中亜鉛値[μg/g Cre]
+0.0052164×尿中Cペプチド値[μg/g Cre]
+0.0082645×年齢
+4.4228686
(推定式2−1)
推定糖化ヘモグロビン(HbA1c)値[%]
=0.0014884×尿中亜鉛値[μg/g Cre]
+0.0098283×年齢
+4.3166251
(推定式3−1)
推定糖化ヘモグロビン(HbA1c)値[%]
=0.0055022×尿中Cペプチド値[μg/g Cre]
+0.0095667×年齢
+4.7510559
(推定式4−1)
推定糖化ヘモグロビン(HbA1c)値[%]
=0.0015105×尿中亜鉛値[μg/g Cre]
+0.0059799×尿中Cペプチド値[μg/g Cre]
+4.5566696
(推定式5−1)
推定糖化ヘモグロビン(HbA1c)値[%]
=0.0015×尿中亜鉛値[μg/g Cre]
+4.7335
HbA1c値と、尿中亜鉛値、推定式1−1〜4−1から推定したHbA1c値との間に相関が認められ、尿中亜鉛値、推定式1−1、2−1、4−1から推定したHbA1c値との間により高い相関が認められ、推定式1−1から推定したHbA1c値との間に最も高い相関が認められた。HbA1c値と、推定式1−1から推定したHbA1c値との相関を図1に示す。
Claims (3)
- 対象者の尿中亜鉛値を指標として、糖化ヘモグロビン(HbA1c)値を推定する方法。
- 対象者の年齢、尿中亜鉛値、尿中Cペプチド値のうちいずれか2つ以上を指標として、糖化ヘモグロビン(HbA1c)値を推定する方法。
- 対象者の年齢、尿中亜鉛値、尿中Cペプチド値を指標として、糖化ヘモグロビン(HbA1c)値を推定する方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019168784A JP7354497B2 (ja) | 2019-09-17 | 2019-09-17 | 非侵襲的なHbA1c値の推定方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019168784A JP7354497B2 (ja) | 2019-09-17 | 2019-09-17 | 非侵襲的なHbA1c値の推定方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021047056A true JP2021047056A (ja) | 2021-03-25 |
JP7354497B2 JP7354497B2 (ja) | 2023-10-03 |
Family
ID=74878258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019168784A Active JP7354497B2 (ja) | 2019-09-17 | 2019-09-17 | 非侵襲的なHbA1c値の推定方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7354497B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023013164A1 (ja) | 2021-08-06 | 2023-02-09 | 日清食品ホールディングス株式会社 | HbA1cリスク推定装置、HbA1cリスク推定方法及びプログラム |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03160367A (ja) * | 1989-11-20 | 1991-07-10 | Denki Kagaku Kogyo Kk | 尿の処理剤 |
JP2016180752A (ja) * | 2015-03-23 | 2016-10-13 | アークレイ株式会社 | 尿検体中の分析対象物量の予測方法 |
-
2019
- 2019-09-17 JP JP2019168784A patent/JP7354497B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03160367A (ja) * | 1989-11-20 | 1991-07-10 | Denki Kagaku Kogyo Kk | 尿の処理剤 |
JP2016180752A (ja) * | 2015-03-23 | 2016-10-13 | アークレイ株式会社 | 尿検体中の分析対象物量の予測方法 |
Non-Patent Citations (4)
Title |
---|
ANGUS G. JONES, TIMOTHY J. MCDONALD, BEVERLEY M. SHIELDS, ANITA V. HILL, CHRISTOPHER J. HYDE, BRIDGE: "Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type", DIABETES CARE, vol. 39 (2):, JPN6023023152, 1 February 2016 (2016-02-01), pages 250 - 257, ISSN: 0005076152 * |
S. KIILERICH, MERETE SANVIG CHRISTENSEN, J. NAESTOFT, C. CHRISTIANSEN,: "Determination of zinc in serum and urine by atomic absorption spectrophotometry; Relationship betwee", CLINICA CHIMICA ACTA,, vol. Volume 105, Issue 2,, JPN6023023151, 4 August 1980 (1980-08-04), pages 231 - 239, ISSN: 0005076153 * |
SOLIMAN, G. Z.: "Serum/Urine Zn Level of Egyptian Type II Diabetic Patients and Its relation with Glycemic Control (H", JOURNAL OF BIOLOGY AND MEDICINE, vol. 3.1, JPN6023023155, 14 August 2019 (2019-08-14), pages 044 - 047, ISSN: 0005076150 * |
VERONICA DA SILVA BANDEIRA, LILIANE VIANA PIRES, LEILA LEIKO HASHIMOTO, LUCIANE LUCA DE ALENCAR, KAL: "Association of reduced zinc status with poor glycemic control in individuals with type 2 diabetes me", JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY,, vol. 44, JPN6023023153, December 2017 (2017-12-01), pages 132 - 136, ISSN: 0005076151 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023013164A1 (ja) | 2021-08-06 | 2023-02-09 | 日清食品ホールディングス株式会社 | HbA1cリスク推定装置、HbA1cリスク推定方法及びプログラム |
Also Published As
Publication number | Publication date |
---|---|
JP7354497B2 (ja) | 2023-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Klein et al. | Association of ocular disease and mortality in a diabetic population | |
Sugisawa et al. | Skin autofluorescence reflects integration of past long-term glycemic control in patients with type 1 diabetes | |
Rodrigues et al. | Ultrasonography and other nutrition assessment methods to monitor the nutrition status of critically ill patients | |
Kuczmarski | Bioelectrical impedance analysis measurements as part of a national nutrition survey | |
Merino et al. | Negative effect of a low-carbohydrate, high-protein, high-fat diet on small peripheral artery reactivity in patients with increased cardiovascular risk | |
Ozkayar et al. | Blood pressure measurements, blood pressure variability and endothelial function in renal transplant recipients | |
Lindau et al. | Minimally invasive and innovative methods for biomeasure collection in population-based research | |
Henault et al. | Capillary measurement of lactate and glucose for free flap monitoring | |
Gadaen et al. | The effects of chronic dialysis on physical status, quality of life, and arterial stiffness: a longitudinal study in prevalent dialysis patients | |
Okazaki et al. | Evaluation of the accuracy of a non-invasive hemoglobin-monitoring device in schoolchildren | |
JP7354497B2 (ja) | 非侵襲的なHbA1c値の推定方法 | |
Derosa et al. | Female Sexual Dysfunction in Subjects with Type 2 Diabetes Mellitus | |
Naik et al. | Comparison and correlation of glucose levels in serum and saliva of patients with diabetes mellitus | |
Schell et al. | Clinical comparison of automatic, noninvasive measurements of blood pressure in the forearm and upper arm with the patient supine or with the head of the bed raised 45: a follow-up study | |
Kuzawa et al. | Ankle brachial index (ABI) in a cohort of older women in the Philippines: Prevalence of peripheral artery disease and predictors of ABI | |
Marks et al. | Small-intestinal mucosa in pemphigoid and subcorneal pustular dermatosis | |
Goh et al. | Ministry of health clinical practice guidelines: screening of cardiovascular disease and risk factors | |
Baum | Home monitoring of diabetic control. | |
O'Brien et al. | Implications of diagnostic delay in Duchenne muscular dystrophy. | |
Culp et al. | Using the Quetelet body mass index as a mortality indicator for patients starting renal replacement therapy | |
Hodes | Screening in general practice | |
Brown et al. | A comparison of neuropathy quality of life tools: Norfolk QOL-DN, PN-QOL-97, and NeuroQOL-28 | |
JP7379767B2 (ja) | 非侵襲的な血清亜鉛値の推定方法 | |
Davis et al. | Association of retinopathy and glycosylated haemoglobin levels in diabetes mellitus | |
Gadallah | Supervised |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220624 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230524 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230727 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230727 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230822 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230828 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7354497 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |